We treated prostate cancer cells with these inhibitors to determine their impacts on AR signaling by measuring AR targeted transcription of PSA, TMPRSS2 and FKBP5 genes (Figure 1d and S2a). This evidence concerns the gene FKBP5 and Familial prostate cancer.